Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lete-cel in synovial sarcoma and myxoid/round cell liposarcoma
NL-OMON58732Phase 2Completed
- Sponsor
- US WorldMeds
- Start
- Jul 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of letetresgene autoleucel in synovial sarcoma (SS) and Myxoid/round cell liposarcoma (MRCLS), sponsored by US WorldMeds. Primary endpoint: Overall Response Rate. Started Jul 2020; status: completed.
02
Drugs
letetresgene autoleucel
03
Conditions
synovial sarcoma (SS)Myxoid/round cell liposarcoma (MRCLS)
Beyond the preview
Go deeper on NL-OMON58732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58732.